BIO
BMY - SEE YOU GUYS ON THE MOON 3M CHART - 85-100+Since 1969 BMY has been around yes. The fact this is chartable is wild. I think we see 70+ in 2-3 weeks 80+ after that new all time highs. I already am accumulating 700+ OTM options.
HAPP - ABOUT TO BE HAPPENINGNo there is nothign wrong with this stock its a typical bio downtrend. I think this is due for a massssssssive move.
I actually rarely pay much attention to indicators regardless how many I have / most the time zoomed in double clicked in just using volume etc. However, to find end of long term downtrends they can be extremely useful on these.
Bollinger Bands (40 day and 14 day overalapping on bottom)
RSI dead on all time frames
Factors:
-Float 16M when this moves it will move even bigger
-Cash to Debt 18 RATIO. They are not at all hurting for cash in fact did direct offering also. Cash is without a doubt good for future far as I can tell.
-Postitive news / Ecommerce etc. I think it pops VERY similar to WNW
KURA - FALLING WEDGE HUGE PLAY HERE OPTIONS OR STOCK All,
I think this has a massive play possible here.
Why:
-Confleunce support (horizontally) + trend support
-Falling wedge downtrend
-40MA tight against trend (if you're a VWAP person I'm sure you would see a VWAP play)
-RSI/MACD both good
Recent news very positive. Looking into options Monday.
VTGN **ON HIGH ALERT** SEE PDSB
All,
I think you see some erie similarities and the extreme HL aka bullish moves and could form ascend bullish triangle here. Earnings is June 29th being bio may or may not matter more than likely nuetral. Regardless solid setup here either way if it pops here and holds the ascend tri / a fall I believe would just set up for the exact same thing which wold be a wider volatile ascend tri as well. Definitely worth watching.
$NMRD entry PTs 10-12 PT 18-19 and higher Nemaura Medical (NMRD) said early Wednesday it received a purchase order for 200,000 sugarBEAT sensors and 5,000 sugarBEAT transmitters from its UK licensee DB Ethitronix.
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
$OCGN best to buy after ER this Fri on 5/7/2021...$OCGN next Target PT 70 and higher, long term PT 180 and higher
$OCGN " The Ocugen team has submitted a comprehensive drug master file with the FDA, and is currently diligently preparing the EUA application, according to Shankar Musunuri, Chairman of the Board, CEO and and co-founder of Ocugen."
$VXRT entry PT 7-8 PT Target PTs 14-17-22Trend-base Fib Extension...
Why Vaxart Stock Is Surging Today
Investors are excited about the company's experimental COVID-19 vaccine.
What happened
Shares of Vaxart (NASDAQ:VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%.
So what
A phase 1 study showed Vaxart's vaccine to potentially be protective against COVID-19, as well as a broad array of other coronavirus-induced illnesses, such as SARS, MERS, and the common cold.
"Our vaccine's immune response appears very different than that seen from the leading injectables: mucosal antibodies rather than serum antibodies, and more potent T-cell responses," Vaxart CEO Andrei Floroiu said in a press release.
T-cells are a type of white blood cells that can seek out and kill virus-infected cells. They are a vital part of the body's ability to generate an adaptive immune response to specific pathogens. Vaxart's drug produced a stronger T-cell response than Pfizer and Moderna's injectable vaccines, according to Vaxart's chief scientific officer, Dr. Sean Tucker.
Now what
Should Vaxart's vaccine candidate prove to be safe and effective in later-stage clinical trials, it could become a welcomed new tool in the battle against COVID-19. In such a scenario, the drug would also provide Vaxart with a powerful new revenue and profit driver.
Joe Tenebruso
(TMFGuardian)
$ATOS entry PTs 2.30 Target PTs 4.75-5.50-7 and higherPivoting off Support and up-trending towards Resistance, time sequence within Wave analysis
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
$VRTX Vertex Short Idea (Bearish head and shoulders)Buy put spreads for April on this name. I think 180/165 put debit 4/19 would do well. XBI is under a lot of pressure, this company has nothing fresh right now, massive head and shoulders.
Get it back in that safe channel
SRNE - Beginning of third wave, maybe..As long as the company continues to provide decent news and progress, I believe this pattern will prove itself.
The market went down hard at yesterday's session and recovered strongly, I believe that SRNE weak hands were washed out in that move and now it will be easier for it to move towards the highs.
If the volume goes down and the price will move sideways/down for more than a week than consider the plan cancelled.
Price broke below the trendline, could be a fakeout! Price broke below the trendline, could be a fakeout! Fundamentals are still strong for equity market, not worrying about crash, but think it could be a good pullback to add some positions here !
ASRT can do this?"Assertio is a pharmaceutical company that sells prescription products in 3 areas: neurology, hospital, and pain and inflammation. The company is currently undergoing major restructuring and has recently merged with Zyla Life Sciences. They have 7 FDA approved products in the marketplace.
Assertio currently has a market cap of only $150 million and has raised $50 million in direct offerings over the past week. ASRT has been on a bullish run with the price is currently up 45% in 1 week and it closed at $1.09 yesterday. This is despite 2 offerings that have been announced. The price skyrocketed off the closure of the first offering priced at $0.62 and I believe it will do the same with the current offering. Prior to the announcement of the recent offering (@$0.98), the price hit $1.45 on Tuesday. Given that the offering will not result in dilution, I believe any price under $1.1 is a good buy point"
Quoting - u/TruePriest
My target is 3$ depending on the earnings report next month. My RR ratio is 1:4
While we speak let's just avg down or up.
(Disclaimer)
(This is not financial advice, just my opinion)
Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment.
I would be looking at the 18.46 area for a retest, and possible entry if we find support.
100% measured move would take the breakout to 23.81 and ultimately that would be my first target.
Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry.
Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level
If we happen to see price action above these levels, i would consider targeting 37$ down the road.
The top of this trading range would be close to $45, Currently trading at 15.49
ETNB long (longer-term play)ETNB long, longer-term play
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Pre-revenue, early stage company.
BIO BUY CALL 600 jun18 6000$ 218days cmp: 599 pro: 1.Health BIO BUY CALL 600 jun18 6000$ 218days
cmp: 599
pro:
1.Health care sector is a hot sector during covid
2. weekly demand and bouncing in daily as confirmation
3.Aggreessive stock
4.Stock making constantly HH HL in weekly demand
BKYI Bio Key International huge upside potentialBIO-key, Provider of Multi-Factor Identity and Access Management Solutions, Hosts Q2 Investor Call Friday, Aug 14 at 10am ET.
Innovative Credit Card Processor Clearent, LLC Switches to BIO-key’s PortalGuard Identity and Access Management Solution to Secure Customer Access and Deliver Secure Reset Capabilities.
Source: yahoo finance
The analysts are targeting a 2usd price per share.
With a market cap of only 16.5 mil but also a debt of 14.5 mil, BKYI is one of the riskiest bets on the market with a huge potential though.
The uprising volume is also a great sign.
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
AGEN - See Past Post - This ride isn't overAll,
See my previous post on my baby aka favorite stock. My entry was $2.28 on this. There pipeline was epic, FDA approvals and no price movement. Now it just hit every scanner and radar out there. I would not buy in now of course, but over time it will come back and retest the last high it left from. It may happen quickly but I would put my alert around 50% of the big bar. I will update later on re buy ins for this stock.
RXMD - Roll the Dice on the OTC?First off, THIS IS A RISKY BET. I got in at .082 yes... less than a dime. There was news they are doing antibody COVID testing. This got 40M volume x8 its relative volume. Like I said extremely risky. Watch it today and see what happens. Personally I just bought 3000 shares because I don't care if I lose $250 just to see.
finance.yahoo.com
AGEN - Add to watchlist ASAP.Read the news on last two AGEN articles.. approved for FDA and beat the EPS... This is a monthly chart and i can at LEAST see x2 profits ahead.
Quick Pump and Dump | THMODo Not Trade This! I'd personally wait for a retest around $6.90 before making my move. Might buy a few shares for fun tomorrow and see how it rolls.
For premium crypto & option signals, direct message me or @Kyer
DotcomJack | Easy Loot
Biod Rad Laboratories $BIO$BIO just broke the pivot but RSI is still below the trend. It may stall on nextweek.
